Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

April 30, 2011

Conditions
Cigarette SmokingSchizophrenia
Interventions
DRUG

varenicline

Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.

DRUG

placebo

At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of Maryland, Baltimore

OTHER

NCT00554840 - Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia | Biotech Hunter | Biotech Hunter